Belite Bio, Inc
NASDAQ:BLTE
62.82 (USD) • At close December 23, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Belite Bio, Inc |
Symbool | BLTE |
Munteenheid | USD |
Prijs | 62.82 |
Beurswaarde | 1,939,839,636 |
Dividendpercentage | 0% |
52-weken bereik | 31.005 - 86.53 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Yu-Hsin Lin M.B.A., Ph.D. |
Website | https://belitebio.com |
An error occurred while fetching data.
Over Belite Bio, Inc
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)